New patent expiration for Gilead Sciences drug COMPLERA – DrugPatentWatch
Annual Drug Patent Expiration for COMPLERA
Complera is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from a single supplier. There are nine patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for COMPLERA.
This drug has three hundred and five patent family members in fifty countries.
The generic ingredient in COMPLERA is emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate. One registered supplier for this compound. Additional details are available on emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published at the expiration of a new patent for the Gilead Sciences drug COMPLERA
